IntelGenx to Promote VetaFilm™ Oral Film Technology at Human Biotech & Animal Health Business Partnering Summit
April 08 2019 - 8:00AM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading
oral drug delivery company, today announced that it will promote
its proprietary VetaFilm™ oral film technology for companion animal
drug delivery at the Human Biotech & Animal Health Business
Partnering Summit taking place on April 9, 2019 in Boston, MA.
VetaFilm™ is a rapidly disintegrating oral film designed to
improve drug performance, promote compliance and increase the ease
of drug administration in companion animals. As small as a postage
stamp, the film can be flavoured to appeal to companion animals for
spontaneous intake and will adhere on contact in the mouth.
Moreover, VetaFilm™ buccal absorption has the potential for
improved drug efficacy, faster onset of action and reduced side
effects by avoiding first-pass metabolism.
VetaFilm™ technology is compatible with a wide variety of
actives such as cannabinoids. According to primary research
conducted by IntelGenx’s team, cannabinoid-containing VetaFilm™
animal health products are in high demand by pet owners. Recent
studies have shown that cannabidiol significantly reduces pain and
improves mobility in dogs with osteoarthritis1.
“We are excited to be a part of the Human Biotech & Animal
Health Business Partnering Summit,” said Horst G. Zerbe, President
and CEO of IntelGenx. “The Summit is an excellent forum to
demonstrate the innovative possibilities with VetaFilm™ and how
this oral film technology can serve unmet medical needs in
veterinary health.”
Reference 1 Gamble L et al., “Pharmacokinetics,
Safety, and Clinical Efficacy of Cannabidiol Treatment in
Osteoarthritic Dogs”, Front. Vet. Sci., 23 July 2018.
About IntelGenx Established in 2003, IntelGenx
is a leading oral drug delivery company primarily focused on the
development and manufacturing of innovative pharmaceutical oral
films based on its proprietary VersaFilm™ and VetaFilmTM technology
platforms.
IntelGenx's highly skilled team provides comprehensive
pharmaceuticals services to pharmaceutical partners, including
R&D, analytical method development, clinical monitoring, IP and
regulatory services. IntelGenx's state-of-the-art manufacturing
facility, which was established for oral film technology platforms,
offers by supporting lab-scale to pilot- and commercial-scale
production. More information about the company can be found
at www.intelgenx.com. Forward Looking
Statements This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx' plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements. Each of the TSX Venture Exchange and OTCQX has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
For IntelGenx:
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Apr 2024 to May 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From May 2023 to May 2024